Next Article in Journal
Anti-Proliferative and Genotoxic Activities of the Helichrysum petiolare Hilliard & B.L. Burtt
Previous Article in Journal
Nephroprotective Effect of the Herbal Composition BNO 2103 in Rats with Renal Failure
Open AccessArticle

Prevalence of Drug Interaction in Severely Obese Individuals and Associated Factors: Baseline Results from a Clinical Trial

1
Post-Graduate Program in Health Sciences, School of Medicine, Federal University of Goiás, Goiás 74605-050, Brazil
2
School of Medicine, Federal University of Goiás, Goiás 74605-050, Brazil
3
Goiás Health Department, Goiás 74860-270, Brazil
4
School of Pharmacy, Federal University of Goiás, Goiás 74605-170, Brazil
*
Authors to whom correspondence should be addressed.
Sci. Pharm. 2020, 88(4), 48; https://doi.org/10.3390/scipharm88040048
Received: 17 September 2020 / Revised: 7 October 2020 / Accepted: 9 October 2020 / Published: 20 October 2020
The prevalence of obesity is increasing worldwide and is commonly associated with comorbidities. The use of several drugs is often necessary, which leads to Potential Drug Interactions (PDI) that may increase the morbidity and mortality. This study aimed to analyze the prevalence of drug interaction and its association with socio-demographics, health status, and drug use in severely obese individuals. Baseline data from a randomized clinical trial registered at Clinicaltrial.gov (NCT02463435) were used. A total of 150 individuals aged 18–65 years with a body mass index of 35 kg/m2 were included. The outcome variable was the presence of PDI, and the explanatory variables were divided into the following four levels: socio-demographic, lifestyle, health, and medication use. The prevalence of PDI was 50% (n = 75) (95% CI 41–58). The variables associated with drug–drug interactions in the multiple analyses were arterial hypertension (PR 1.83, 95%, CI 1.10–3.04), polypharmacy (PR 3.12, 95%, CI 2.17–4.50), and diabetes mellitus (PR 0.60, 95%, CI 0.45–0.81). The risk factors for the occurrence of drug interaction were the presence of diabetes mellitus, hypertension, and polypharmacy. View Full-Text
Keywords: severe obesity; drug interaction; drug utilization reviews; randomized controlled trial; pharmacoepidemiology severe obesity; drug interaction; drug utilization reviews; randomized controlled trial; pharmacoepidemiology
Show Figures

Figure 1

MDPI and ACS Style

Modesto, A.C.F.; Silveira, E.A.; dos Santos Rodrigues, A.P.; Lima, D.M.; Provin, M.P.; Amaral, R.G. Prevalence of Drug Interaction in Severely Obese Individuals and Associated Factors: Baseline Results from a Clinical Trial. Sci. Pharm. 2020, 88, 48.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop